WO1993016756A1 - Cardiac pacemaker with hysteresis behavior - Google Patents

Cardiac pacemaker with hysteresis behavior Download PDF

Info

Publication number
WO1993016756A1
WO1993016756A1 PCT/US1993/000052 US9300052W WO9316756A1 WO 1993016756 A1 WO1993016756 A1 WO 1993016756A1 US 9300052 W US9300052 W US 9300052W WO 9316756 A1 WO9316756 A1 WO 9316756A1
Authority
WO
WIPO (PCT)
Prior art keywords
rate
pacing
avg
interval
lrhi
Prior art date
Application number
PCT/US1993/000052
Other languages
French (fr)
Inventor
Richard Sutton
Ivan Bourgeois
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Publication of WO1993016756A1 publication Critical patent/WO1993016756A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/365Heart stimulators controlled by a physiological parameter, e.g. heart potential

Definitions

  • the present invention relates to cardiac pacemakers, and more specifically to a pacemaker having a selectable hysteresis feature which compensates for sinus node
  • Atrial or ventricular stimulations induced by such devices as cardiac pacemakers generally delay or inhibit natural heart activity by preventing the depolarization of the sinus node.
  • the hysteresis feature was developed to address this concern, by allowing the pacemaker to follow the sensed sinus node depolarization to a certain predetermined rate below the programmed lower rate of the pacemaker.
  • the escape interval in conventional demand pacemakers equipped with hysteresis feature is longer than the lower rate interval, for enabling the patient's intrinsic rhythm to control the heart as long as the intrinsic rate is maintained above a predetermined minimum rate.
  • these conventional pacemakers do not generally allow the natural heart activity to resume
  • the Sholder patent proposes to vary the hysteresis rate as a function of the pacemaker sensor rate, to a predetermined level upon sensing of the natural heart contraction during the escape interval, as illustrated in Figure 3B and 4.
  • PACER issued to Roline et al, on December 14, 1982, and assigned to Medtronic, Inc., discloses a multiple-mode pacer which automatically switches from an atrial synchronous mode to a ventricular inhibited mode when the intrinsic atrial rate drops below a preset hysteresis rate.
  • the Roline patent is incorporated herein by reference.
  • the pacemaker has a programmable lower rate and upper rate, a programmable lower hysteresis rate (LRH)
  • LRHI lower rate hysteresis interval
  • IR programmable rate
  • UR upper pacing rate
  • LRHI lower rate hysteresis interval
  • the pacemaker stimulates at the lower rate hysteresis (LRH) and thereafter gradually increases the pacing rate up to the intermediate rate (IR) while the pulse generator is in the demand mode.
  • a time counter maintains a continuous pacing at the intermediate rate (IR) for a predefined period of time, and the pacing rate is gradually decreased down to the lower pacing rate (LR).
  • Figure 1 is a block diagram showing the primary
  • FIGS. 2A and 2B are flow charts of a simplified software program suitable for use in the pacemaker of Figure
  • Figure 3 is an illustration of two exemplary generally increasing limit functions SL 1 and SL 2 which determine the behavior of the pacemaker according to the software program of Figures 2A and 2B;
  • Figure 4 is a response curve illustrating the variation of the pacing rate according to the present invention.
  • Figure 5 is another response curve illustrating pacing rate variation according to the present invention.
  • Figure 6 is yet another response curve illustrating pacing rate variation according to the present invention.
  • Block 150 illustrates a microprocessor chip, such as the CDP 1802 microprocessor made by RCA.
  • the microprocessor 150 is connected to a ROM memory 151 and to a RAM memory 152 via a data bus 156.
  • An address bus 154 interconnects the ROM memory 151, the RAM memory 152, and a controller circuit 158.
  • the controller circuit 158 controls a pacer circuit 161 and a pacemaker output stage 160 for stimulating the heart.
  • the pacemaker 100 could be used for single chamber or dual chamber pacing.
  • FIGS. 2A and 2B together illustrate the flow diagram of a program 200 which is stored in the ROM memory 151, and which is run once each cycle in the pacemaker 100.
  • the program 200 could, be stored in the RAM memory 152.
  • the program 200 does not contain all the steps which are carried out by the microprocessor 150, but it includes those steps that illustrate the operation of the pacemaker 100 according to the present invention. Several variables of the software-controlled operations can be reprogrammed through the RAM memory 152.
  • Intrinsic rhythm or “intrinsic rate” of the heart is the rate at which the heart naturally beats on its own, without being stimulated by a pacemaker-provided stimulus.
  • Hysteresis means extension of the range of rates at which inhibition of the pacemaker pulses will occur. The base pacing interval is increased by the hysteresis
  • Pacing Rate is the rate at which the stimulation pulses are provided from the heart from the pacemaker.
  • the program 200 is initiated, and the intrinsic ventricular depolarizations are sensed at 202. While the program 200 uses ventricular events for carrying out the invention, it should be understood that atrial events can alternatively be used.
  • the program 200 measures, at step 204, the intrinsic escape interval, such as the RR interval between two successive sensed ventricular events, and calculates, at step 206, a parameter "D" , as follows:
  • RR i-1 is the RR interval preceding
  • the absolute value of D represents the rate of change of the intervals of the intrinsic ventricular
  • step 208 If at step 208 the value of D is found to be negative, this value will not be used since it represents an increase in the intrinsic ventricular depolarization rate, and the above subroutine, including steps 202, 204, 206 and step 208, is repeated until a positive value of D is found.
  • the preferred embodiment of the present invention relates principally to precipitous drops in heart rates, and consequently only positive values of D are added and stored at 212 by the random access memory RAM 152.
  • the feature of selecting between consecutive and positive D values is a programmable feature, and is selectable by the attending physician.
  • the software 200 calculates the average rate of increase M AVG of a preselected number
  • M AVG is calculated over a predetermined period of time "T". If during that period T, the value of M AVG is less than a first limit function SL 1 , then this is an indication that the intrinsic heart rate has not dropped rapidly enough to warrant the use of corrective measures, such as the activation of the hysteresis feature. If on the other hand, the value of M AVG reaches or exceeds the first limit SL 1 , but is less than a second limit SL 2 , the pacemaker is instructed to take appropriate measures, as will be described later in greater detail.
  • the program 200 stores the calculated positive values of D, at step 212, and counts the number of events "n" indicative of a positive D value. When the count reaches a preprogrammed number "N" of stored beats or reaches the time period T, the program 200 calculates the sum "M" of the N stored values D, as follows:
  • j is an integer that varies between 1 and N; and where N is the number of stored beats.
  • the value of M is then averaged at step 217 over the number of stored beats N, as follows:
  • N 6 beats.
  • LRI means the Lower Rate Interval which corresponds to the lower pacing rate "LR" of the pacemaker. LR is typically programmed to 70 beats per minute.
  • LRHI means the Lower Rate Hysteresis Interval that corresponds to the lower rate hysteresis "LRH" which is typically programmed to 50 beats per minute.
  • Region I is the portion of the quadrant defined by the lower limit function SL 1 and by the RRI and time axes.
  • the pacemaker 100 operates in Region I whenever the value of
  • M AVG is less than SL 1 ; and the last intrinsic ventricular escape interval RR N is shorter than the lower rate
  • hysteresis interval LRHI Pacing is inhibited in Region I, as illustrated by the curve KL in Figure 4, and by step 222 of Figure 2A.
  • the curve KL shows the heart rate decreasing at a slow rate.
  • Region II is the portion of the quadrant defined by the limit functions SL 1 and SL 2 , and by the lower rate hysteresis interval LRHI axis.
  • the pacemaker 100 operates in Region II whenever the value of M AVG is greater than SL 1 , but less than SL 2 ; and the last intrinsic ventricular escape interval RR N is shorter than LRHI. Pacing is inhibited in Region II, as illustrated by the curve AB in Figures 5 and 6, and by step 236 of Figure 2B.
  • the curve AB shows the heart rate decreasing at an intermediate rate.
  • Region III is the portion of the quadrant defined by the upper limit function SL 2 , by the RRI axis and by the lower rate hysteresis interval LRHI axis.
  • the pacemaker 100 operates in Region III whenever the value of M AVG is greater than SL 2 ; and the last intrinsic escape interval RR N is shorter than LRHI. Pacing is inhibited in Region III, as illustrated by the curve K'L in Figure 4, and by the step
  • Regular IV is the portion of the quadrant above the lower rate hysteresis interval LRHI axis, and defined by the
  • pacing is carried out at the lower rate LR. It should however be understood that pacing could alternatively occur at LRH.
  • Region V will be the portion of the quadrant above the lower rate hysteresis interval LRHI axis, between the two limit functions SL 1 and SL 2 .
  • the pacemaker 100 operates in Region V whenever the value of M AVG is less than SL 2 but greater than SL 1 , and the last intrinsic escape interval RR N is longer than LRHI.
  • pacing starts at the lower rate hysteresis rate LRH and gradually increases until the pacing rate reaches an intermediate pacing rate IR.
  • Pacing at IR is maintained for a predetermined period of time, and is thereafter gradually reduced until it reaches the lower rate LR. Pacing is maintained at the lower rate until the intrinsic rate exceeds the pacemaker lower rate, as illustrated by the curve FGH in Figure 5, and the curve RS in Figure 5.
  • the pacemaker operation in Region V is
  • the pacemaker 100 operates in Region VI whenever the value of M AVG is less than SL 1 ; and the last intrinsic ventricular escape interval RR N will be longer than the lower rate hysteresis interval LRHI. As illustrated by the curve LPQ in Figure 4, and by the step 224 of Figure 2A, pacing is carried out at the lower rate LR. It should however be understood that pacing could alternatively occur at LRH.
  • the program 200 compares M AVG to SL 1 and step 218. If M AVG is less than SL 1 , then a further determination is made at step 220 whether the last ventricular intrinsic escape interval RR N is less than or equal to LRHI. If it is, the pacemaker 100 operates in Region I, and pacing is inhibited, as indicated by step 222 in Figure 2A and by the response curve KL in Figure 4.
  • the pacemaker 100 will operate in Region IV, and stimulation is carried out at the lower pacing rate LR, as illustrated by the curve LPQ in
  • M AVG is less than or equal to SL 2 . If M AVG is found to be greater than SL 2 then the pacemaker 100 will operate in either Region III or Region IV. A further decision is made at step 228 whether the last intrinsic escape interval RR N is less than or equal to the lower rate hysteresis interval (LRHI).
  • LRHI lower rate hysteresis interval
  • the pacemaker 100 will operate in Region III, and as indicated by step 232 of Figure 2B, and by the curve K'L in Figure 4, pacing will be inhibited. If. on the other hand, it is determined at step 228, that RR N is greater than LRHI, then the pacemaker 100 will operate in
  • pacing is carried out at the lower pacing rate (LR).
  • the pacemaker 100 identifies and reacts to intermediat drops in the intrinsic heart rate, whenever M AVG is found to be intermediate the limit functions SL 1 and SL 2 , as follows:
  • the pacemaker is caused to pace at a gradually increasing pacing rate until it reaches a predetermined intermediate pacing rate (IR) which is lower than, or in certain circumstances, equal to, the upper pacing rate (UR).
  • IR intermediate pacing rate
  • UR upper pacing rate
  • Demand pacing is maintained at the intermediate pacing rate (IR) for a predetermined period of time, and is thereafter reduced gradually.
  • the program 200 determines at step 234 whether the last intrinsic escape interval RR N is less than or equal to LRHI. If it is, then the pacemaker
  • RR N will tend to be longer than LRHI
  • the condition set forth in equation (6) above is satisfied, and the pacemaker 100 will operate in Region V, and will respond by pacing at the lower rate hysteresis (LRH) for a predetermined period of time or a preset number of beats, as illustrated by the dashed line
  • the pacemaker 100 could alternatively bypass step 238 and start pacing along curve BC ( Figure 5), with one paced beat at the lower rate hysteresis (LRH).
  • pacing is started at point B ( Figure 5) and the pacing rate is incrementally increased until it reaches the intermediate rate (IR).
  • the intermediate rate IR is programmable, and could be changed by the attending physician.
  • the incremental increase in the pacing rate is illustrated by the curves BC in Figures 5 and
  • the incremental increase of the pacing rate is achieved by steps 240 through 244, whereby the value of the pacing rate is incrementally increased by a value X (step 240), and a determination is made at step 242 whether the pacing rate is less than or equal to IR.
  • a time counter is set to maintain the continuous pacing at that intermediate rate (IR) for a preselected programmable period of time, such as for five minutes. This continuous pacing at the intermediate rate is illustrated by curve CD in Figures 5 and 6. If during the execution of the subroutine 244 through 248, an intrinsic rhythm is sensed at 245, then the intrinsic rate prevails, and pacing is inhibited.
  • the pacing rate is gradually decreased from the intermediate pacing rate (IR), toward the lower pacing rate (LR). This decrement is achieved by the subroutine 250 - 252, where the pacing rate is decreased by an incremental value Y until the pacing rate reaches the lower rate LR.
  • the pacemaker 100 If decremental pacing is maintained until it reaches the lower rate LR, the pacemaker 100 starts pacing at that lower rate, as illustrated by the curve EF in Figure 5, and the routine 200 is repeated. If an intrinsic rhythm is sensed at any time during the decremental change (curve DE') in the pacing rate, then the intrinsic rate prevails, and pacing is inhibited, as illustrated by the curve E'RS in Figure 6. The subroutine 200 is thereafter repeated.
  • the new approach described in the present invention teaches away from the conventional hysteresis response feature.
  • the natural heart rate resumes and is tracked until it reaches the hysteresis rate. Thereafter, the pacing rate is increased until the
  • intermediate rate is maintained for a predetermined period of time, and thereafter allowed to gradually decay toward the lower rate.
  • the present invention can be made an integral part of single chamber and dual chamber pacemakers which operate in one or more of the programmed modes: SSI, SSIR, DDD, DDDR, DVI, DVIR, DDI and/or DDIR.
  • the present hysteresis feature can be applied to the atrial and/or ventricular channels of a dual chamber pacemaker.

Abstract

A pacemaker having a hysteresis feature which permits intrinsic heart activity, controlled by the sinus node to resume optimally after pacing. The pacemaker has a programmable lower rate and upper rate, a programmable lower hysteresis rate (LRH) corresponding to a lower rate hysteresis interval (LRHI), and a programmable rate (IR) intermediate an upper pacing rate (UR) and a lower pacing rate (LR). A microprocessor measures the average rate of change MAVG? in the intervals between consecutive ventricular depolarizations, and compares the last intrinsic escape interval RRN? to the lower rate hysteresis interval (LRHI). If the last intrinsic escape interval RRN? is longer than the lower rate hysteresis interval (LRHI), and if the value of MAVG? is greater than a first preselected value SL1? but less than a second preselected value SL2?, the pacemaker stimulates at the lower rate hysteresis (LRH) and thereafter gradually increases the pacing rate up to the intermediate rate (IR). A time counter maintains a continuous pacing at the intermediate rate (IR) for a predefined period of time, and the pacing rate is gradually decreased toward the lower pacing rate (LR).

Description

CARDIAC PACEMAKER WITH HYSTERESIS BEHAVIOR
BACKGROUND OF THE INVENTION
The present invention relates to cardiac pacemakers, and more specifically to a pacemaker having a selectable hysteresis feature which compensates for sinus node
malfunction.
It is well known that natural heart activity, including the depolarization of the sinus node provides optimum hemodynamic performance. Atrial or ventricular stimulations induced by such devices as cardiac pacemakers, generally delay or inhibit natural heart activity by preventing the depolarization of the sinus node.
The hysteresis feature was developed to address this concern, by allowing the pacemaker to follow the sensed sinus node depolarization to a certain predetermined rate below the programmed lower rate of the pacemaker. As such, the escape interval in conventional demand pacemakers equipped with hysteresis feature, is longer than the lower rate interval, for enabling the patient's intrinsic rhythm to control the heart as long as the intrinsic rate is maintained above a predetermined minimum rate. However, in selected patients, these conventional pacemakers do not generally allow the natural heart activity to resume
normally after pacing.
The following patents provide a brief historical background for the development and use of the hysteresis feature as it relates to cardiac pacing technology. U.S. Patent No. 4,856,523, entitled "RATE-RESPONSIVE PACEMAKER WITH AUTOMATIC MODE SWITCHING AND/OR VARIABLE HYSTERESIS RATE," issued to Sholder et al, on August 15, 1989,
describes the inclusion of the hysteresis feature in a rate-responsive pacemaker, in an attempt to prevent competition between the pacemaker and the heart's SA node, when the anterograde conduction path is restored. The Sholder patent proposes to vary the hysteresis rate as a function of the pacemaker sensor rate, to a predetermined level upon sensing of the natural heart contraction during the escape interval, as illustrated in Figure 3B and 4.
U.S. Patent No. 4,363,325 entitled "MODE ADAPTIVE
PACER," issued to Roline et al, on December 14, 1982, and assigned to Medtronic, Inc., discloses a multiple-mode pacer which automatically switches from an atrial synchronous mode to a ventricular inhibited mode when the intrinsic atrial rate drops below a preset hysteresis rate. The Roline patent is incorporated herein by reference.
While the above cited patents and other publications and studies relating to the hysteresis feature have
attempted with varying degrees of success to allow the patient's intrinsic rhythm to control, none was completely successful in causing the natural heart activity to resume optimally after pacing.
SUMMARY OF THE INVENTION Briefly, the above and further objects and features of the present invention are realized by providing a new and improved pacemaker having a hysteresis feature which permits intrinsic heart activity, controlled by the sinus node to resume optimally after pacing.
The pacemaker has a programmable lower rate and upper rate, a programmable lower hysteresis rate (LRH)
corresponding to a lower rate hysteresis interval (LRHI), and a programmable rate (IR) intermediate an upper pacing rate (UR) and a lower pacing rate (LR). A microprocessor measures the average rate of change in the intervals between consecutive ventricular depolarizations MAVG, and compares the last intrinsic escape (RRN) interval to the lower rate hysteresis interval (LRHI). If the last intrinsic ventricular interval (RRN) will be longer than the lower rate hysteresis interval (LRHI), and if the value of MAVG is greater than a first preselected value SL1 but less than a second preselected value SL2, the pacemaker stimulates at the lower rate hysteresis (LRH) and thereafter gradually increases the pacing rate up to the intermediate rate (IR) while the pulse generator is in the demand mode. A time counter maintains a continuous pacing at the intermediate rate (IR) for a predefined period of time, and the pacing rate is gradually decreased down to the lower pacing rate (LR).
The accompanying Table I summarizes the features offered by the present invention, and correlates these features to Figures 2A through 6.
Figure imgf000006_0001
BRIEF DESCRIPTION OF THE DRAWINGS
The above and other options, features and advantages of the present invention will be more apparent from the
following more particular description thereof, presented in conjunction with accompanying drawings, wherein:
Figure 1 is a block diagram showing the primary
functional blocks of the pacemaker according to the present invention;
Figures 2A and 2B are flow charts of a simplified software program suitable for use in the pacemaker of Figure
1;
Figure 3 is an illustration of two exemplary generally increasing limit functions SL1 and SL2 which determine the behavior of the pacemaker according to the software program of Figures 2A and 2B;
Figure 4 is a response curve illustrating the variation of the pacing rate according to the present invention;
Figure 5 is another response curve illustrating pacing rate variation according to the present invention; and
Figure 6 is yet another response curve illustrating pacing rate variation according to the present invention.
DESCRIPTION OF THE PREFERRED EMBODIMENT
Referring now to the drawings and more particularly to Figure 1 thereof, there is illustrated a block diagram of the components of the pacemaker 100 of the present
invention. Block 150 illustrates a microprocessor chip, such as the CDP 1802 microprocessor made by RCA. The microprocessor 150 is connected to a ROM memory 151 and to a RAM memory 152 via a data bus 156. An address bus 154 interconnects the ROM memory 151, the RAM memory 152, and a controller circuit 158. The controller circuit 158, in turn, controls a pacer circuit 161 and a pacemaker output stage 160 for stimulating the heart. The pacemaker 100 could be used for single chamber or dual chamber pacing.
Figures 2A and 2B together illustrate the flow diagram of a program 200 which is stored in the ROM memory 151, and which is run once each cycle in the pacemaker 100.
Alternatively, the program 200 could, be stored in the RAM memory 152. The program 200 does not contain all the steps which are carried out by the microprocessor 150, but it includes those steps that illustrate the operation of the pacemaker 100 according to the present invention. Several variables of the software-controlled operations can be reprogrammed through the RAM memory 152.
Before proceeding with a more detailed explanation of the present invention, it would be helpful to review the following definitions:
"Intrinsic rhythm" or "intrinsic rate" of the heart is the rate at which the heart naturally beats on its own, without being stimulated by a pacemaker-provided stimulus.
"Hysteresis" means extension of the range of rates at which inhibition of the pacemaker pulses will occur. The base pacing interval is increased by the hysteresis
interval. Thus, hysteresis provides a longer escape
interval, thereby giving the heart an opportunity to beat on its own before the pacer provides stimulation pulses.
"Pacing Rate" is the rate at which the stimulation pulses are provided from the heart from the pacemaker.
Starting at step 201, the program 200 is initiated, and the intrinsic ventricular depolarizations are sensed at 202. While the program 200 uses ventricular events for carrying out the invention, it should be understood that atrial events can alternatively be used.
The program 200 measures, at step 204, the intrinsic escape interval, such as the RR interval between two successive sensed ventricular events, and calculates, at step 206, a parameter "D" , as follows:
D = RRi - RRi-1, (1) where RRi is the RR interval which has been recently
measured at step 204; and RRi-1 is the RR interval preceding
RR;. It therefore follows that the parameter D is
indicative of the rate of change of the RR interval.
In this respect, if D were found to have a positive value, it is an indication that the RR interval is
increasing with time, and consequently the intrinsic rate of the heart is dropping. The reverse holds true where D has a negative value, indicating that the RR interval is
decreasing and that the intrinsic rate is increasing.
Additionally, the absolute value of D represents the rate of change of the intervals of the intrinsic ventricular
depolarizations, which is also illustrated by the slope the curve AB in Figures 5 and 6, as it will be described later in greater detail.
If at step 208 the value of D is found to be negative, this value will not be used since it represents an increase in the intrinsic ventricular depolarization rate, and the above subroutine, including steps 202, 204, 206 and step 208, is repeated until a positive value of D is found. The dashed line 207 indicates that if the value of D is found to be negative, then the attending physician will have the option to either cause the software to set n=O, at step 203, or to restart at step 202. The preferred embodiment of the present invention relates principally to precipitous drops in heart rates, and consequently only positive values of D are added and stored at 212 by the random access memory RAM 152.
While the preferred embodiment includes adding only those positive values of D, it will become apparent to those skilled in the art that consecutive D values could
alternatively be added. The feature of selecting between consecutive and positive D values is a programmable feature, and is selectable by the attending physician.
In order to detect and ascertain the occurrence of precipitous heart rate drops, the software 200 calculates the average rate of increase MAVG of a preselected number
"N" of RR intervals. Preferably, MAVG is calculated over a predetermined period of time "T". If during that period T, the value of MAVG is less than a first limit function SL1, then this is an indication that the intrinsic heart rate has not dropped rapidly enough to warrant the use of corrective measures, such as the activation of the hysteresis feature. If on the other hand, the value of MAVG reaches or exceeds the first limit SL1, but is less than a second limit SL2, the pacemaker is instructed to take appropriate measures, as will be described later in greater detail.
To achieve this function, the program 200 stores the calculated positive values of D, at step 212, and counts the number of events "n" indicative of a positive D value. When the count reaches a preprogrammed number "N" of stored beats or reaches the time period T, the program 200 calculates the sum "M" of the N stored values D, as follows:
Figure imgf000010_0001
where j is an integer that varies between 1 and N; and where N is the number of stored beats.
The value of M is then averaged at step 217 over the number of stored beats N, as follows:
Figure imgf000010_0002
In the preferred mode of the present invention the above parameters are assigned the following values: N = 6 beats.
T = 15 seconds.
It should, however, be understood that different values or ranges of values can alternatively be employed within the scope of the invention.
Digressing from the flow chart of Figure 2A, and turning to Figure 3, there is a shown lower limit function SL1 and an upper limit function SL2 which are identified by the numeral references 10 and 12, and which divide the quadrant into six regions: I, II, III, IV, V and VI. Each one of these regions will now be described in greater detail in relation to Figures 2A through 5. The horizontal
coordinate axis represents time "t", and the vertical coordinate axis represents RR intervals "RRI".
As used in this specification, the LRI and LRHI parameters in the following context:
"LRI" means the Lower Rate Interval which corresponds to the lower pacing rate "LR" of the pacemaker. LR is typically programmed to 70 beats per minute.
"LRHI" means the Lower Rate Hysteresis Interval that corresponds to the lower rate hysteresis "LRH" which is typically programmed to 50 beats per minute.
By comparing the average rate of change MAVG to the programmable limit functions SL1 and SL2, it would be
possible to identify the region which corresponds to the mode of operation of the pacemaker 100. For clarity
purposes, the six regions are defined as follows:
"Region I" is the portion of the quadrant defined by the lower limit function SL1 and by the RRI and time axes. The pacemaker 100 operates in Region I whenever the value of
MAVG is less than SL1; and the last intrinsic ventricular escape interval RRN is shorter than the lower rate
hysteresis interval LRHI. Pacing is inhibited in Region I, as illustrated by the curve KL in Figure 4, and by step 222 of Figure 2A. The curve KL shows the heart rate decreasing at a slow rate.
"Region II" is the portion of the quadrant defined by the limit functions SL1 and SL2, and by the lower rate hysteresis interval LRHI axis. The pacemaker 100 operates in Region II whenever the value of MAVG is greater than SL1, but less than SL2; and the last intrinsic ventricular escape interval RRN is shorter than LRHI. Pacing is inhibited in Region II, as illustrated by the curve AB in Figures 5 and 6, and by step 236 of Figure 2B. The curve AB shows the heart rate decreasing at an intermediate rate.
"Region III" is the portion of the quadrant defined by the upper limit function SL2, by the RRI axis and by the lower rate hysteresis interval LRHI axis. The pacemaker 100 operates in Region III whenever the value of MAVG is greater than SL2; and the last intrinsic escape interval RRN is shorter than LRHI. Pacing is inhibited in Region III, as illustrated by the curve K'L in Figure 4, and by the step
232 of Figure 2B. The curve K'L shows the heart rate decreasing precipitously.
"Region IV" is the portion of the quadrant above the lower rate hysteresis interval LRHI axis, and defined by the
RRI axis and by the upper limit function SL2. The pacemaker
100 operates in Region IV whenever the value of MAVG is greater than SL2; and the last intrinsic escape interval RRN will be longer than LRHI. As illustrated by the curve LPQ in Figure 4, and by the step 230 of figure 2B, pacing is carried out at the lower rate LR. It should however be understood that pacing could alternatively occur at LRH.
"Region V" will be the portion of the quadrant above the lower rate hysteresis interval LRHI axis, between the two limit functions SL1 and SL2. The pacemaker 100 operates in Region V whenever the value of MAVG is less than SL2 but greater than SL1, and the last intrinsic escape interval RRN is longer than LRHI. As illustrated by the curves BCDEF and BB'CDE'R in Figures 5 and 6 respectively, and by steps 238 through 254 of Figure 2B, pacing starts at the lower rate hysteresis rate LRH and gradually increases until the pacing rate reaches an intermediate pacing rate IR. Pacing at IR is maintained for a predetermined period of time, and is thereafter gradually reduced until it reaches the lower rate LR. Pacing is maintained at the lower rate until the intrinsic rate exceeds the pacemaker lower rate, as illustrated by the curve FGH in Figure 5, and the curve RS in Figure 5. The pacemaker operation in Region V is
triggered by an intermediate rate of decrease in the
intrinsic heart rate.
"Region VI" is the portion of the quadrant defined by the lower limit function and by the lower limit function
SL1. The pacemaker 100 operates in Region VI whenever the value of MAVG is less than SL1; and the last intrinsic ventricular escape interval RRN will be longer than the lower rate hysteresis interval LRHI. As illustrated by the curve LPQ in Figure 4, and by the step 224 of Figure 2A, pacing is carried out at the lower rate LR. It should however be understood that pacing could alternatively occur at LRH.
Returning now to Figure 2A, the program 200 compares MAVG to SL1 and step 218. If MAVG is less than SL1, then a further determination is made at step 220 whether the last ventricular intrinsic escape interval RRN is less than or equal to LRHI. If it is, the pacemaker 100 operates in Region I, and pacing is inhibited, as indicated by step 222 in Figure 2A and by the response curve KL in Figure 4.
If the intrinsic escape interval (RRN) is determined at step 220, to be equal to or tend to exceed LRHI, and if there is no sensed event at a shorter interval, while the pacemaker is still in the demand mode, the pacemaker 100 will operate in Region IV, and stimulation is carried out at the lower pacing rate LR, as illustrated by the curve LPQ in
Figure 4. The curves in Figures 4, 5 and 6 which are drawn in dashed lines indicate that pacing is inhibited, while the curves drawn in solid lines indicate that pacing is
occurring.
Returning now to step 218 in the flow chart of Figure
2A, if the program 200 determines that MAVG is greater than or equal to SL1 then a further determination is made at step
226 whether MAVG is less than or equal to SL2. If MAVG is found to be greater than SL2 then the pacemaker 100 will operate in either Region III or Region IV. A further decision is made at step 228 whether the last intrinsic escape interval RRN is less than or equal to the lower rate hysteresis interval (LRHI).
If the program 200 determines that RRN is less than or equal to LRHI then the pacemaker 100 will operate in Region III, and as indicated by step 232 of Figure 2B, and by the curve K'L in Figure 4, pacing will be inhibited. If. on the other hand, it is determined at step 228, that RRN is greater than LRHI, then the pacemaker 100 will operate in
Region IV and as indicated by step 230 of Figure 2B, and by the curve LPQ in Figure 4, pacing is carried out at the lower pacing rate (LR).
The pacemaker 100 identifies and reacts to intermediat drops in the intrinsic heart rate, whenever MAVG is found to be intermediate the limit functions SL1 and SL2, as follows:
SL1 ≤ MAVG≤ SL2 (4)
In the above condition, the pacemaker is caused to pace at a gradually increasing pacing rate until it reaches a predetermined intermediate pacing rate (IR) which is lower than, or in certain circumstances, equal to, the upper pacing rate (UR). Demand pacing is maintained at the intermediate pacing rate (IR) for a predetermined period of time, and is thereafter reduced gradually.
With reference to Figure 2B, the program 200 determines at step 234 whether the last intrinsic escape interval RRN is less than or equal to LRHI. If it is, then the pacemaker
100 will operate in Region II, and as indicated by step 236, and by the curve AB in Figures 5 and 6, pacing is inhibited.
If however, it is determined at step 234 that RRN will tend to be longer than LRHI, then the condition set forth in equation (6) above is satisfied, and the pacemaker 100 will operate in Region V, and will respond by pacing at the lower rate hysteresis (LRH) for a predetermined period of time or a preset number of beats, as illustrated by the dashed line
BB' in Figure 6, and by step 238 in Figure 2B.
It should however be understood that the pacemaker 100 could alternatively bypass step 238 and start pacing along curve BC (Figure 5), with one paced beat at the lower rate hysteresis (LRH). In this respect, pacing is started at point B (Figure 5) and the pacing rate is incrementally increased until it reaches the intermediate rate (IR). The intermediate rate IR is programmable, and could be changed by the attending physician. The incremental increase in the pacing rate is illustrated by the curves BC in Figures 5 and
6. During this period, the pacemaker 100 is in the
inhibited mode for single chamber pacemakers, or in the DDD mode for dual chamber pacemakers.
The incremental increase of the pacing rate is achieved by steps 240 through 244, whereby the value of the pacing rate is incrementally increased by a value X (step 240), and a determination is made at step 242 whether the pacing rate is less than or equal to IR. Once IR is reached, then, as indicated by step 244, a time counter is set to maintain the continuous pacing at that intermediate rate (IR) for a preselected programmable period of time, such as for five minutes. This continuous pacing at the intermediate rate is illustrated by curve CD in Figures 5 and 6. If during the execution of the subroutine 244 through 248, an intrinsic rhythm is sensed at 245, then the intrinsic rate prevails, and pacing is inhibited.
Once the counter time lapses, then, as illustrated by the curves DE and DE' in Figure 5 and 6 respectively, the pacing rate is gradually decreased from the intermediate pacing rate (IR), toward the lower pacing rate (LR). This decrement is achieved by the subroutine 250 - 252, where the pacing rate is decreased by an incremental value Y until the pacing rate reaches the lower rate LR.
If decremental pacing is maintained until it reaches the lower rate LR, the pacemaker 100 starts pacing at that lower rate, as illustrated by the curve EF in Figure 5, and the routine 200 is repeated. If an intrinsic rhythm is sensed at any time during the decremental change (curve DE') in the pacing rate, then the intrinsic rate prevails, and pacing is inhibited, as illustrated by the curve E'RS in Figure 6. The subroutine 200 is thereafter repeated.
It is therefore clear that the new approach described in the present invention teaches away from the conventional hysteresis response feature. In the present invention, whenever an intermediate drop in the heart rate occurs and the hysteresis feature is activated, the natural heart rate resumes and is tracked until it reaches the hysteresis rate. Thereafter, the pacing rate is increased until the
intermediate rate (IR) is reached. Pacing at that
intermediate rate is maintained for a predetermined period of time, and thereafter allowed to gradually decay toward the lower rate.
It should become apparent to those skilled in the art after reviewing the present description, that the present invention can be made an integral part of single chamber and dual chamber pacemakers which operate in one or more of the programmed modes: SSI, SSIR, DDD, DDDR, DVI, DVIR, DDI and/or DDIR. The present hysteresis feature can be applied to the atrial and/or ventricular channels of a dual chamber pacemaker.
While the following ranges reflect exemplary values of
IR, LR, UR, LRH, SL1 and SL2, it should be understood to those skilled in the art that other values and ranges can also be employed and/or programmed.
100 bpm ≤ UR ≤ 150 bpm.
80 bpm ≤ IR ≤ 100 bpm.
60 bpm ≤ LR ≤ 80 bpm.
40 bpm ≤ LRH ≤ 60 bpm.
2 % ≤ SL1 ≤ 10 %.
5 % ≤ SL2 ≤ 20 %.
4 beats ≤ N ≤ 16 beats
While particular embodiments of the present invention have been disclosed, it is to be understood that various different modifications are possible and are contemplated within the scope and spirit of the specification, drawings, abstract, and appended claims.

Claims

What is claimed is:
1. In a pacemaker having a programmable lower rate and upper rate, a programmable lower hysteresis rate (LRH) corresponding to a lower rate hysteresis interval (LRHI), and a programmable intermediate pacing rate (IR) the
improvement comprising:
A. means for measuring the rate of change MAVG of
successive cardiac intrinsic escape intervals;
B. means for comparing MAVG to a first predefined
limit SL1;
C. means for comparing the last intrinsic escape
interval to the lower rate hysteresis interval (LRHI); and
D. means for stimulating at the lower rate hysteresis (LRH) and for gradually incrementing the pacing rate until it reaches the intermediate pacing rate (IR) if the last intrinsic escape interval is longer than the lower rate hysteresis interval (LRHI) and if said MAVG is greater than SL1.
2. The pacemaker according to claim 1 further
including:
A. time counter means for maintaining continuous
pacing at the intermediate rate (IR) for a predefined period of time; and B. means for allowing gradual decay of the pacing rate after said selected period of time has lapsed.
3. The pacemaker according to claim 1, wherein said means for measuring the rate of change MAVG includes:
A. means for measuring intervals between two
successive ventricular depolarizations (RR
intervals); and
B. means for averaging the rate of change MAVG of
said successive RR intervals.
4. The pacemaker according to claim 3, wherein said means for averaging the rate of change of said RR intervals includes:
A. means for calculating the difference D between two successive RR intervals;
B. means for comparing the value of said difference D to a predetermined reference value;
C. means for storing those values of D which are
greater than said reference value;
D. means for calculating the sum M of N stored values of D, wherein N is a predetermined positive integer; and
E. means for setting MAVG equal to M .
5. The pacemaker according to claim 4, wherein said means for averaging MAVG includes means for averaging the values of D greater than said reference value over a
predefined period of time.
6. The pacemaker according to claim 5, wherein said reference value is zero, and wherein only positive values of D are stored and added.
7. The pacemaker according to claim 3, further includes means for comparing MAVG to a second predetermined limit SL2 having a value greater than that of SL1.
8. The pacemaker according to claim 7, wherein said means for stimulating gradually increments the pacing rate until it reaches the intermediate pacing rate (IR), if the last intrinsic escape interval RRN is longer than LRHI, and if MAVG is greater than or equal to SL1 but less than or equal to SL2.
9. The pacemaker according to claim 4, wherein N is set equal to six beats.
10. The pacemaker according to claim 2, wherein said selected programmable time is set equal to five minutes.
11. The pacemaker according to claim 3, further including means for inhibiting stimulation if MAVG is less than SL1, and if the last intrinsic escape interval RRN is less than or equal to LRHI.
12. The pacemaker according to claim 11, further including means for stimulating at the lower rate if MAVG is less than SL1, and if the RRN interval will be greater than LRHI.
13. The pacemaker according to claim 7, further including means for inhibiting stimulation if MAVG is greater than SL2, and if the RRN interval is less than or equal to LRHI.
14. The pacemaker according to claim 13, further including means for stimulating at the lower rate if MAVG is greater than SL2, and if the RRN interval will be longer than LRHI.
15. The pacemaker according to claim 13, further including:
A. means for inhibiting stimulation if MAVG is
greater than SL2, and if the RRN interval is less than or equal to LRH; and B. means for stimulating at the lower rate if MAVG is greater than SL2, and if the RRN interval will be longer than LRHI.
16. Method for pacing with a pacemaker having a programmable lower rate and upper rate, a programmable lower hysteresis rate (LRH) corresponding to a lower rate
hysteresis interval (LRHI), and a programmable intermediate pacing rate (IR), the pacing method comprising the steps of:
A. measuring the rate of change MAVG of successive
intrinsic escape intervals;
B. comparing MAVG to a first predetermined limit SL1;
C. comparing said last intrinsic escape interval to the lower rate hysteresis interval (LRHI); and
D. stimulating at the lower rate hysteresis (LRH) and gradually incrementing the pacing rate until it reaches the intermediate pacing rate (IR) if the RRN interval will be longer than the lower rate hysteresis interval (LRHI) and if said MAVG is greater than SL1.
17. The pacing method according to claim 16 further including the steps of:
A. maintaining continuous pacing at the intermediate rate (IR) for a predefined period of time; and B. allowing gradual decay of the pacing rate after said selected period of time has lapsed.
18. The pacing method according to claim 17, wherein said step of measuring the rate of change MAVG includes:
A. measuring intervals between two successive
ventricular depolarizations (RR intervals); and B. averaging the rate of change MAVG of said
successive RR intervals;
19. The pacing method according to claim 18, wherein said step of averaging the rate of change of said RR intervals includes:
A. calculating the difference D between two
successive RR intervals;
B. comparing the value of said difference D to a
predetermined reference value;
C. storing those values of D which are greater than said reference value;
D. calculating the sum M of N stored values of D, wherein N is a predetermined positive integer; an E. setting MAVG equal to .
Figure imgf000025_0001
20. The pacing method according to claim 19, further including the step comparing MAVG to a second predetermined limit SL2 having a value greater than that of SL1.
21. The pacing method according to claim 20, wherein said step of stimulating includes gradually incrementing the pacing rate until it reaches the intermediate pacing rate (IR), if the RRN interval will be longer than LRHI, and if MAVG is greater than or equal to SL, but less than or equal to SL2.
22. The pacing method according to claim 18, further including:
A. the step of inhibiting stimulation if MAVG is less than SL1, and if the last sensed RR interval is less than or equal to LRHI;
B. the step of stimulating at the lower rate if MAVG is less than SL1, and if the RRN interval will be longer than LRHI;
C. the step of inhibiting stimulation if MAVG is
greater than SL2, and if the RRN interval is less than or equal to LRHI; and
D. the step of stimulating at the lower rate if MAVG is greater than SL2, and if the RRN interval will be longer than LRHI.
PCT/US1993/000052 1992-02-27 1993-01-04 Cardiac pacemaker with hysteresis behavior WO1993016756A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/842,818 US5284491A (en) 1992-02-27 1992-02-27 Cardiac pacemaker with hysteresis behavior
US07/842,818 1992-02-27

Publications (1)

Publication Number Publication Date
WO1993016756A1 true WO1993016756A1 (en) 1993-09-02

Family

ID=25288311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/000052 WO1993016756A1 (en) 1992-02-27 1993-01-04 Cardiac pacemaker with hysteresis behavior

Country Status (3)

Country Link
US (2) US5284491A (en)
AU (1) AU3433193A (en)
WO (1) WO1993016756A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501701A (en) * 1994-04-29 1996-03-26 Medtronic, Inc. Pacemaker with vasovagal syncope detection and therapy
WO1996015828A1 (en) * 1994-11-22 1996-05-30 Medtronic, Inc. Sinus preference method and apparatus for cardiac pacemakers
EP0745410A1 (en) * 1995-05-31 1996-12-04 ELA MEDICAL (Société anonyme) Active implantable medical device, especially pacemaker or defibrillator
WO1997041922A1 (en) * 1996-05-03 1997-11-13 Medtronic, Inc. Arrhythmia and fibrillation prevention pacemaker using consistent pacing
WO1998015319A1 (en) * 1996-10-04 1998-04-16 Pacesetter Ab Implantable device

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540728A (en) * 1994-05-20 1996-07-30 Medtronic, Inc. Pacemaker with vasovagal snycope detection
AU2117195A (en) 1994-04-29 1995-11-29 Medtronic, Inc. Pacemaker with vasovagal syncope detection
US5676686A (en) * 1994-05-20 1997-10-14 Medtronic, Inc. Pacemaker with vasovagal syncope detection
US5725561A (en) * 1995-06-09 1998-03-10 Medtronic, Inc. Method and apparatus for variable rate cardiac stimulation
US5759196A (en) * 1995-09-29 1998-06-02 Medtronic, Inc. Modification of pacemaker tachy response based on FFRW sensing
US5814083A (en) 1995-09-29 1998-09-29 Medtronic, Inc Pacemaker tachy determination based blocked on 2:1 sensing
US7167748B2 (en) * 1996-01-08 2007-01-23 Impulse Dynamics Nv Electrical muscle controller
ATE290905T1 (en) * 1996-01-08 2005-04-15 Impulse Dynamics Nv DEVICE FOR CONTROLLING HEART ACTIVITY USING NON-EXCITING PRE-STIMULATION
IL125424A0 (en) 1998-07-20 1999-03-12 New Technologies Sa Ysy Ltd Pacing with hemodynamic enhancement
US8825152B2 (en) * 1996-01-08 2014-09-02 Impulse Dynamics, N.V. Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue
US8321013B2 (en) 1996-01-08 2012-11-27 Impulse Dynamics, N.V. Electrical muscle controller and pacing with hemodynamic enhancement
US9289618B1 (en) 1996-01-08 2016-03-22 Impulse Dynamics Nv Electrical muscle controller
US9713723B2 (en) 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
US6415178B1 (en) * 1996-09-16 2002-07-02 Impulse Dynamics N.V. Fencing of cardiac muscles
DE19623046A1 (en) * 1996-05-28 1997-12-04 Biotronik Mess & Therapieg Pacemaker with hysteresis function
US5706829A (en) * 1996-06-06 1998-01-13 Creighton University Method for treating neurocardiogenic syncope
US7840264B1 (en) 1996-08-19 2010-11-23 Mr3 Medical, Llc System and method for breaking reentry circuits by cooling cardiac tissue
US7908003B1 (en) 1996-08-19 2011-03-15 Mr3 Medical Llc System and method for treating ischemia by improving cardiac efficiency
US5782886A (en) 1997-02-28 1998-07-21 Vitatron Medical, B.V. Pacemaker with improved hysteresis
FR2763247B1 (en) * 1997-05-16 2000-02-18 Ela Medical Sa ACTIVE IMPLANTABLE MEDICAL DEVICE, IN PARTICULAR A CARDIAC STIMULATOR, DEFIBRILLATOR AND / OR CARDIOVERTER FOR REDUCING ARRHYTHMIA EPISODES, ESPECIALLY ATRIAL ARRHYTHMIA
US5991659A (en) * 1998-09-30 1999-11-23 Vitatron Medical, B.V. Pacing system with full range sudden rate drop detection and responsive pacing intervention
US6725093B1 (en) 1998-11-06 2004-04-20 Impulse Dynamics N.V. Regulation of excitable tissue control of the heart based on physiological input
AU1072100A (en) 1998-11-06 2000-05-29 Impulse Dynamics N.V. Trigger-based regulation of excitable tissue control in the heart
US6675043B1 (en) 1998-11-06 2004-01-06 Impulse Dynamics N.V. Sensor-based regulation of excitable tissue control of the heart
AU1072200A (en) * 1998-11-06 2000-05-29 Impulse Dynamics N.V. Sensor-based regulation of excitable tissue control of the heart
MXPA01007820A (en) * 1999-02-04 2003-06-19 Technion Res & Dev Foundation Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells.
US6049735A (en) * 1999-03-01 2000-04-11 Cardiac Pacemakers Inc. Cardiac rhythm management device with detection and therapy for sudden syncopal events
US8666495B2 (en) * 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US8346363B2 (en) * 1999-03-05 2013-01-01 Metacure Limited Blood glucose level control
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8700161B2 (en) * 1999-03-05 2014-04-15 Metacure Limited Blood glucose level control
US8019421B2 (en) * 1999-03-05 2011-09-13 Metacure Limited Blood glucose level control
US20040249421A1 (en) * 2000-09-13 2004-12-09 Impulse Dynamics Nv Blood glucose level control
US7203535B1 (en) 1999-04-01 2007-04-10 Cardiac Pacemakers, Inc. System and method for classifying tachycardia arrhythmias having 1:1 atrial-to-ventricular rhythms
US6430438B1 (en) 1999-05-21 2002-08-06 Cardiac Pacemakers, Inc. Cardiac rhythm management system with atrial shock timing optimization
US7181278B2 (en) * 1999-05-21 2007-02-20 Cardiac Pacemakers, Inc. Apparatus and method for ventricular rate regularization
US6351669B1 (en) 1999-05-21 2002-02-26 Cardiac Pacemakers, Inc. Cardiac rhythm management system promoting atrial pacing
US7212860B2 (en) * 1999-05-21 2007-05-01 Cardiac Pacemakers, Inc. Apparatus and method for pacing mode switching during atrial tachyarrhythmias
US8064997B2 (en) * 1999-05-21 2011-11-22 Cardiac Pacemakers, Inc. Method and apparatus for treating irregular ventricular contractions such as during atrial arrhythmia
US7062325B1 (en) * 1999-05-21 2006-06-13 Cardiac Pacemakers Inc Method and apparatus for treating irregular ventricular contractions such as during atrial arrhythmia
US6285907B1 (en) 1999-05-21 2001-09-04 Cardiac Pacemakers, Inc. System providing ventricular pacing and biventricular coordination
US6501988B2 (en) 2000-12-26 2002-12-31 Cardiac Pacemakers Inc. Apparatus and method for ventricular rate regularization with biventricular sensing
US7142918B2 (en) * 2000-12-26 2006-11-28 Cardiac Pacemakers, Inc. Apparatus and method for pacing mode switching during atrial tachyarrhythmias
US6993385B1 (en) * 1999-10-25 2006-01-31 Impulse Dynamics N.V. Cardiac contractility modulation device having anti-arrhythmic capabilities and a method of operating thereof
US7027863B1 (en) 1999-10-25 2006-04-11 Impulse Dynamics N.V. Device for cardiac therapy
AU1049901A (en) 1999-10-25 2001-05-08 Impulse Dynamics N.V. Cardiac contractility modulation device having anti-arrhythmic capabilities and a method of operating thereof
US7239914B2 (en) * 2000-05-13 2007-07-03 Cardiac Pacemakers, Inc. Rate smoothing control
US6501987B1 (en) * 2000-05-26 2002-12-31 Cardiac Pacemakers, Inc. Rate smoothing control
US7039461B1 (en) 2000-05-13 2006-05-02 Cardiac Pacemakers, Inc. Cardiac pacing system for prevention of ventricular fibrillation and ventricular tachycardia episode
US6647295B2 (en) 2000-05-15 2003-11-11 Pacesetter, Inc. Implantable cardiac stimulation device with detection and therapy for patients with vasovagal syncope
US6625492B2 (en) 2000-05-15 2003-09-23 Pacesetter, Inc. Implantable cardiac stimulation device with detection and therapy for patients with vasovagal syncope
US8512220B2 (en) * 2000-05-26 2013-08-20 Cardiac Pacemakers, Inc. Rate smoothing control
US6424865B1 (en) * 2000-07-13 2002-07-23 Cardiac Pacemakers, Inc. Ventricular conduction delay trending system and method
US6522922B1 (en) 2000-07-13 2003-02-18 Cardiac Pacemakers, Inc. Method and apparatus for breaking pacemaker mediated bradycardia
US6829504B1 (en) 2000-09-14 2004-12-07 Cardiac Pacemakers, Inc. System and method for preventing recurrence of atrial tachyarrhythmia
US6512951B1 (en) 2000-09-14 2003-01-28 Cardiac Pacemakers, Inc. Delivery of atrial defibrillation shock based on estimated QT interval
US20020099414A1 (en) 2000-12-04 2002-07-25 Xander Evers Method and system for preventing the recurrence of atrial fibrillation by an implantable medical device
US20020087198A1 (en) * 2000-12-29 2002-07-04 Kramer Andrew P. Apparatus and method for ventricular rate regularization
US6957100B2 (en) * 2000-12-26 2005-10-18 Cardiac Pacemakers, Inc. Method and system for display of cardiac event intervals in a resynchronization pacemaker
US6889078B2 (en) 2001-04-26 2005-05-03 Medtronic, Inc. Hysteresis activation of accelerated pacing
US6895275B2 (en) 2002-01-22 2005-05-17 Medtronic, Inc. Methods and apparatus for detection and treatment of syncope
PT1509256E (en) 2002-05-24 2009-10-15 Angiotech Int Ag Compositions and methods for coating medical implants
US7400928B2 (en) 2002-10-11 2008-07-15 Cardiac Pacemakers, Inc. Methods and devices for detection of context when addressing a medical condition of a patient
US7372455B2 (en) 2003-02-10 2008-05-13 N-Trig Ltd. Touch detection for a digitizer
US11439815B2 (en) 2003-03-10 2022-09-13 Impulse Dynamics Nv Protein activity modification
WO2004080533A1 (en) * 2003-03-10 2004-09-23 Impulse Dynamics Nv Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue
US7027865B2 (en) * 2003-04-16 2006-04-11 Medtronic, Inc. Pacemaker with vasovagal syncope detection and therapy
US8792985B2 (en) * 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US7076290B2 (en) * 2003-10-10 2006-07-11 Medtronic, Inc. Method and apparatus for detecting and discriminating arrhythmias
US7319900B2 (en) 2003-12-11 2008-01-15 Cardiac Pacemakers, Inc. Cardiac response classification using multiple classification windows
US8521284B2 (en) 2003-12-12 2013-08-27 Cardiac Pacemakers, Inc. Cardiac response classification using multisite sensing and pacing
US7194307B2 (en) * 2003-12-22 2007-03-20 Cardiac Pacemakers, Inc. Pacing method and device for preserving native conduction system
US8352031B2 (en) * 2004-03-10 2013-01-08 Impulse Dynamics Nv Protein activity modification
US8548583B2 (en) * 2004-03-10 2013-10-01 Impulse Dynamics Nv Protein activity modification
US11779768B2 (en) 2004-03-10 2023-10-10 Impulse Dynamics Nv Protein activity modification
US7676262B1 (en) 2004-04-20 2010-03-09 Pacesetter, Inc. Methods and devices for determining exercise compliance diagnostics
US7031766B1 (en) 2004-04-20 2006-04-18 Pacesetter, Inc. Methods and devices for determining exercise diagnostic parameters
DE202004009224U1 (en) * 2004-06-14 2004-08-12 Isra Vision Systems Ag Sensor for measuring the surface of an object
EP1827571B1 (en) 2004-12-09 2016-09-07 Impulse Dynamics NV Protein activity modification
US7761162B2 (en) * 2004-12-13 2010-07-20 Cardiac Pacemakers, Inc. Capture verification with intrinsic response discrimination
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
WO2006097934A2 (en) * 2005-03-18 2006-09-21 Metacure Limited Pancreas lead
US7392088B2 (en) * 2005-04-28 2008-06-24 Cardiac Pacemakers, Inc. Capture detection for multi-chamber pacing
US7907997B2 (en) * 2005-05-11 2011-03-15 Cardiac Pacemakers, Inc. Enhancements to the detection of pulmonary edema when using transthoracic impedance
AU2006259415B2 (en) * 2005-06-15 2012-08-30 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US7529578B2 (en) * 2005-07-12 2009-05-05 Cardiac Pacemakers, Inc. Multi channel approach to capture verification
US20070096897A1 (en) * 2005-10-31 2007-05-03 Welch Allyn, Inc. Attachment/location monitoring of a signal generating entity
US20070129641A1 (en) * 2005-12-01 2007-06-07 Sweeney Robert J Posture estimation at transitions between states
US7826897B2 (en) * 2005-12-22 2010-11-02 Cardiac Pacemakers, Inc. Cardiac pacemaker with pacing rate monitoring
US8326431B2 (en) * 2006-04-28 2012-12-04 Medtronic, Inc. Implantable medical device for the concurrent treatment of a plurality of neurological disorders and method therefore
US8504153B2 (en) 2007-04-04 2013-08-06 Pacesetter, Inc. System and method for estimating cardiac pressure based on cardiac electrical conduction delays using an implantable medical device
US8208999B2 (en) 2007-04-04 2012-06-26 Pacesetter, Inc. System and method for estimating electrical conduction delays from immittance values measured using an implantable medical device
WO2009075749A1 (en) * 2007-12-11 2009-06-18 Cardiac Pacemakers, Inc. Lv unipolar sensing or pacing vector
JP5438687B2 (en) 2007-12-13 2014-03-12 カーディアック ペースメイカーズ, インコーポレイテッド A system that provides unipolar detection vectors
US9320448B2 (en) 2008-04-18 2016-04-26 Pacesetter, Inc. Systems and methods for improved atrial fibrillation (AF) monitoring
EP2365962B1 (en) 2008-11-07 2017-07-05 Massachusetts Institute of Technology Aminoalcohol lipidoids and uses thereof
US8929983B2 (en) * 2008-11-10 2015-01-06 Cardiac Pacemakers, Inc. Reverse hysteresis and mode switching for intermittent pacing therapy
PT2506857T (en) 2009-12-01 2018-05-14 Translate Bio Inc Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
WO2012126503A1 (en) 2011-03-18 2012-09-27 St. Jude Medical Ab Hemodynamic status assessment
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
SI2717893T1 (en) 2011-06-08 2019-10-30 Translate Bio Inc Lipid nanoparticle compositions and methods for mrna delivery
US8478407B2 (en) * 2011-07-28 2013-07-02 Medtronic, Inc. Methods for promoting intrinsic activation in single chamber implantable cardiac pacing systems
EP3536787A1 (en) 2012-06-08 2019-09-11 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
KR102311614B1 (en) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna compositions and related methods and uses
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
CA2928078A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger rna
CN105658242A (en) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 MRNA therapy for phenylketonuria
AU2014340092B2 (en) 2013-10-22 2019-09-19 Translate Bio, Inc. mRNA therapy for Argininosuccinate Synthetase Deficiency
CN110511927A (en) 2014-04-25 2019-11-29 川斯勒佰尔公司 The purification process of mRNA
JP6557722B2 (en) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Biodegradable lipids for delivery of nucleic acids
CN111588695A (en) 2014-06-24 2020-08-28 川斯勒佰尔公司 Stereochemically enriched compositions for delivery of nucleic acids
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
MA47603A (en) 2017-02-27 2020-01-01 Translate Bio Inc NEW ARNM CFTR WITH OPTIMIZED CODONS
US10864378B2 (en) 2017-03-09 2020-12-15 Cardiac Pacemakers, Inc. Pacemaker with diagnostic intrinsic beat search
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
CN112930396A (en) 2018-08-24 2021-06-08 川斯勒佰尔公司 Method for purifying messenger RNA

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313442A (en) * 1980-07-21 1982-02-02 Cardiac Pacemakers, Inc. Atrial rate sensitive cardiac pacer apparatus
EP0326629A1 (en) * 1988-02-01 1989-08-09 Pacesetter AB Pacer with a hysteresis function
US4856523A (en) * 1987-10-08 1989-08-15 Siemens-Pacesetter, Inc. Rate-responsive pacemaker with automatic mode switching and/or variable hysteresis rate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1300416A (en) * 1969-04-16 1972-12-20 Nat Res Dev Improvements in or relating to cardiac pacemakers
US3857399A (en) * 1970-03-24 1974-12-31 F Zacouto Heart pacer
US3921642A (en) * 1974-07-01 1975-11-25 Thomas A Preston Automatic rate adjustment pacer with natural rate searching means and method of operation
US4169480A (en) * 1977-08-19 1979-10-02 Biotronik Mess- Und Therapiegerate Gmbh & Co. Demand pacer with programmable rate hysteresis
US4363325A (en) * 1981-01-19 1982-12-14 Medtronic, Inc. Mode adaptive pacer
US4972834A (en) * 1988-09-30 1990-11-27 Vitatron Medical B.V. Pacemaker with improved dynamic rate responsiveness

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313442A (en) * 1980-07-21 1982-02-02 Cardiac Pacemakers, Inc. Atrial rate sensitive cardiac pacer apparatus
US4856523A (en) * 1987-10-08 1989-08-15 Siemens-Pacesetter, Inc. Rate-responsive pacemaker with automatic mode switching and/or variable hysteresis rate
EP0326629A1 (en) * 1988-02-01 1989-08-09 Pacesetter AB Pacer with a hysteresis function

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501701A (en) * 1994-04-29 1996-03-26 Medtronic, Inc. Pacemaker with vasovagal syncope detection and therapy
WO1996015828A1 (en) * 1994-11-22 1996-05-30 Medtronic, Inc. Sinus preference method and apparatus for cardiac pacemakers
EP0745410A1 (en) * 1995-05-31 1996-12-04 ELA MEDICAL (Société anonyme) Active implantable medical device, especially pacemaker or defibrillator
FR2734730A1 (en) * 1995-05-31 1996-12-06 Ela Medical Sa ACTIVE IMPLANTABLE MEDICAL DEVICE, PARTICULARLY CARDIAC STIMULATOR OR DEFRABRILLATOR
US5702424A (en) * 1995-05-31 1997-12-30 Ela Medical S.A. Method and apparatus for controlling the change of an escape interval in an active implantable medical device
WO1997041922A1 (en) * 1996-05-03 1997-11-13 Medtronic, Inc. Arrhythmia and fibrillation prevention pacemaker using consistent pacing
WO1998015319A1 (en) * 1996-10-04 1998-04-16 Pacesetter Ab Implantable device
US6246909B1 (en) 1996-10-04 2001-06-12 Pacesetter Ab Implantable cardiac stimulator wherein the pacing rate is controlled dependent on variations in the spontaneous interval

Also Published As

Publication number Publication date
AU3433193A (en) 1993-09-13
USRE37454E1 (en) 2001-11-27
US5284491A (en) 1994-02-08

Similar Documents

Publication Publication Date Title
US5284491A (en) Cardiac pacemaker with hysteresis behavior
EP0621055B1 (en) Rate adaptive pacemaker with adjustment of sensor rate as a function of sensed sinus rate
US5441523A (en) Forced atrioventricular synchrony dual chamber pacemaker
EP0796129B1 (en) Cardiac pacemakers using sinus preference method
EP0596598B1 (en) Cardiac rhythm management device with automatic optimization of performance related pacing parameters
US6501988B2 (en) Apparatus and method for ventricular rate regularization with biventricular sensing
EP1105188B1 (en) apparatus for prevention of atrial tachyarrhythmias
US5549649A (en) Programmable pacemaker including an atrial rate filter for deriving a filtered atrial rate used for switching pacing modes
US5318594A (en) DDD type cardiac pacemaker having automatic operating mode switching
US7142918B2 (en) Apparatus and method for pacing mode switching during atrial tachyarrhythmias
EP0360668B1 (en) Dual chamber rate responsive pacemaker
US5085215A (en) Metabolic demand driven rate-responsive pacemaker
US7856267B2 (en) Apparatus and method for pacing mode switching during atrial tachyarrhythmias
EP0363015B1 (en) Rate stabilization pacemaker
EP0652029B1 (en) Rate adaptive dual chamber pacing system with automatic adjustment of operating parameters for minimizing sensor-sinus competition
US4644954A (en) Rate adaptive pacemaker apparatus and method
EP0559193A2 (en) Implantable pacemaker providing hysteresis in dual-chamber modes
JP4347699B2 (en) Pacemaker with adaptive arrhythmia detection window
EP0148486B1 (en) Improved rate adaptive pacemaker apparatus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA